Recent Updates
Recently added Catalysts
CLDI Positive Sentiment

Scientific Advisory Board Member Interview – W.K. Alfred Yung, M.D.

Saturday, February 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article features an interview with W.K. Alfred Yung, M.D., a member of the Scientific Advisory Board. It emphasizes his insights and contributions to the field of oncology. The interview is part of a series showcasing key figures in biotherapeutics. The discussion is expected to provide valuable perspectives on cancer therapies.
Price reaction · baseline $95.988 (2024-02-02 close) · hit after-hours · clean, no other CLDI news in the window
day 0 close
-6.3%
day 1
-2.9%
day 3 · peak
-26%

Market Sentiment Analysis

POSITIVE FACTORS

  • Highlighting expertise of W.K. Alfred Yung, M.D.
  • Focus on innovative approaches in cancer treatment.

Full Press Release Details

Scientific Advisory Board Member Interview – W.K. Alfred Yung, M.D. Interviews & Media February 3, 2024 Next Post Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference Previous Post Scientific Advisory Board Member Interview – Santosh Kesari, M.D./Ph.D.

Frequently Asked Questions

Who is W.K. Alfred Yung, M.D.?

W.K. Alfred Yung, M.D. is a member of the Scientific Advisory Board specializing in oncology.

What topics are covered in the interview?

The interview discusses insights and contributions to cancer treatment and biotherapeutics.

ShareAdd on Google
Tags: CLDI Viatris Investor Conferences Healthcare Calidi Biotherapeutics oncology cancer treatment Scientific Advisory Board W.K. Alfred Yung
Last updated: Feb 3, 2024

Biotech snapshot

Cash runway
$4M liquidity · $1M/mo burn
~2 mo
High dilution risk